HC Wainwright Forecasts Innoviva FY2027 Earnings

Innoviva, Inc. (NASDAQ:INVA) – Research analysts at HC Wainwright issued their FY2027 EPS estimates for shares of Innoviva in a research note issued to investors on Monday, March 2nd. HC Wainwright analyst R. Selvaraju anticipates that the biotechnology company will post earnings per share of $2.50 for the year. HC Wainwright has a “Buy” rating and a $46.00 price objective on the stock. The consensus estimate for Innoviva’s current full-year earnings is $0.33 per share.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $1.60. The firm had revenue of $114.61 million during the quarter, compared to analyst estimates of $102.62 million. Innoviva had a net margin of 65.92% and a return on equity of 37.63%.

INVA has been the subject of several other research reports. Zacks Research lowered shares of Innoviva from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Innoviva in a report on Monday, December 29th. Cantor Fitzgerald increased their price target on shares of Innoviva from $29.00 to $31.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Finally, BTIG Research reissued a “buy” rating and set a $35.00 price objective on shares of Innoviva in a research report on Thursday, February 26th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $38.17.

Innoviva Stock Performance

Shares of INVA opened at $22.18 on Thursday. The firm has a market capitalization of $1.66 billion, a P/E ratio of 7.27 and a beta of 0.42. The company has a debt-to-equity ratio of 0.22, a current ratio of 14.64 and a quick ratio of 13.85. Innoviva has a one year low of $16.52 and a one year high of $25.15. The business has a fifty day moving average of $21.09 and a 200 day moving average of $20.14.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Elevation Point Wealth Partners LLC bought a new position in shares of Innoviva in the second quarter worth about $43,000. EverSource Wealth Advisors LLC boosted its position in shares of Innoviva by 297.7% during the second quarter. EverSource Wealth Advisors LLC now owns 2,398 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 1,795 shares during the last quarter. Danske Bank A S purchased a new position in Innoviva during the third quarter valued at $55,000. Asset Management One Co. Ltd. bought a new stake in Innoviva in the 3rd quarter valued at $60,000. Finally, Toth Financial Advisory Corp bought a new position in shares of Innoviva during the 3rd quarter valued at about $63,000. Hedge funds and other institutional investors own 99.12% of the company’s stock.

More Innoviva News

Here are the key news stories impacting Innoviva this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and set a $46.00 price target, providing fundamental support for a higher valuation if the firm’s longer‑term forecasts materialize. Article Title
• Positive Sentiment: The analyst now projects much stronger FY2027 earnings of $2.50 per share, signaling expected improvement in cash flow or royalty income beyond 2026 that could drive upside over the next 12–24 months. Article Title
• Neutral Sentiment: HC Wainwright provided a detailed set of quarterly EPS forecasts for 2027 (Q1: $0.53, Q2: $0.65, Q3: $0.63, Q4: $0.69), which clarifies the firm’s expectations but will matter only if actual results or company guidance track those numbers. Article Title
• Negative Sentiment: HC Wainwright trimmed FY2026 EPS to $1.96 from $2.23, lowering near‑term earnings expectations and creating downward pressure on the stock while investors digest the reduced 2026 outlook. Article Title
• Negative Sentiment: Multiple 2026 quarterly estimates were cut (Q1 2026: $0.42 from $0.45; Q2 2026: $0.51 from $0.56; Q3 2026: $0.48 from $0.57; Q4 2026: $0.55 from $0.66), increasing concern about near‑term earnings momentum and likely contributing to today’s price decline. Article Title

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.